演題詳細

ポスター / Poster

ポスター 26 (Poster 26) :B細胞性リンパ腫:Chemotherapy

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
塚本 憲史 (Norifumi Tsukamoto):1
1:群馬大学医学部附属病院 腫瘍センター
 
前へ戻る

Efficacy of 90Y-Iburitumomab-Tiuxetan for B cell lymphoma: 22 cases experience in single institute

演題番号 : PS-1-196

山本 和彦 (Kazuhiko Yamamoto):1、逸見 麻衣 (Mai Henmi):1、清家 圭介 (Keisuke Seike):1、三道 康永 (Yasuhisa Sando):1、石川 立則 (Tatsunori Ishikawa):1、原 嘉孝 (Yoshitaka Hara):1、牧田 雅典 (Masanori Makita):1、今城 健二 (Kenji Imajo):1

1:Department of Hematology and Oncology, Okayama City Hospital, Japan

 

Backgrounds: 90Y-iburitumomab-tiuxetan (90YIT) can be used as the alternative therapy against the refractory indolent B cell lymphoma and mantle cell lymphoma (MCL) from 2008. More recently, Bendamustine also became available from 2010. But the consensus of standard therapy applied for the refractory cases of these types of lymphoma has not established yet. We herein report 22 cases treated with 90YIT in our institute. Patients and methods: 22 patients (14 Male, 8 Female) were treated with 90YIT. The median age of the patients was 66 (39-86). The types of lymphoma were follicular lymphoma (FL):13, MCL:6, MALT:2 and undetermined:1. The median time period from diagnosis to the treatment was 33 months (9-267). The median number of prior regimen was 2 (1-6). 4 patients had received Auto PBSCT before. Results: Overall response rate (ORR) was 77.3% (8CR + 9PR). The average overall survival (OS) was 34.7 months, the median progression free survival (PFS) was 14.0 months. 3 patients died in one year after 90YIT administration (infection:1, disease progression:2). For the patients with FL versus MCL, the average OS was 37.9 versus 32.3 months, and the median PFS was 29 versus 6 months, respectively (p=0.01). 8 of 14 relapsed patients received R-Bendamustine. OS of the relapsed patients after 90YIT was 34.1 months, similar to the OS of all patients, suggested salvage therapy could compensate the survival. Conclusion: 90YIT can achieve high response rate, but the long term efficacy seems to be limited. Therefore, we should focus on to establish the standard combined therapy.

前へ戻る